8.98

4.91% 0.42

After Hours: 8.99 0.010 +0.11%

4 D Molecular Therapeutics Inc (FDMT)

Overview News Price History Option Chain Financials Discussions Forecast

4 D Molecular Therapeutics Inc stock is traded at $8.98, with a volume of 727.99K. It is up +4.91% in the last 24 hours and down -2.07% over the past month. 4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.

Previous Close:

$8.56

Open:

$9.94

24h Volume:

727.99K

Relative Volume:

0.84

Market Cap:

$458.05M

Revenue:

$120.00K

Net Income/Loss:

$-209.18M

P/E Ratio:

-2.2815

EPS:

-3.936

Net Cash Flow:

$-185.05M

1W Performance:

+6.27%

1M Performance:

-2.07%

6M Performance:

+36.06%

1Y Performance:

+136.94%

1-Day Range:

$8.56

$9.94

1-Week Range:

$8.21

$9.94

52-Week Range:

$2.235

$12.34

4 D Molecular Therapeutics Inc Stock (FDMT) Company Profile

Name

4 D Molecular Therapeutics Inc

Sector

Healthcare (1114)

Industry

Biotechnology (621)

Phone

(510) 505-2680

Address

5858 HORTON STREET #455, EMERYVILLE

Employee

227

Twitter

Next Earnings Date

2026-03-20

Latest SEC Filings

FDMT's Discussions on Twitter

Compare FDMT vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
FDMT 4 D Molecular Therapeutics Inc	8.98	436.63M	120.00K	-209.18M	-185.05M	-3.936
VRTX Vertex Pharmaceuticals Inc	458.05	114.72B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	737.45	78.67B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	684.50	42.38B	4.16B	1.29B	734.26M	19.59
ALNY Alnylam Pharmaceuticals Inc	311.10	41.75B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	282.72	31.33B	5.36B	287.73M	924.18M	2.5229

4 D Molecular Therapeutics Inc Stock (FDMT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-28-26	Resumed	Barclays	Overweight
Nov-07-25	Upgrade	Morgan Stanley	Underweight → Equal-Weight
Jan-13-25	Downgrade	BMO Capital Markets	Outperform → Market Perform
Nov-21-24	Initiated	Morgan Stanley	Underweight
Sep-23-24	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Apr-15-24	Initiated	Barclays	Overweight
Feb-07-24	Resumed	Goldman	Buy
Oct-26-23	Initiated	RBC Capital Mkts	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-18-23	Upgrade	Leerink Partners	Market Perform → Outperform
Jul-05-23	Initiated	Chardan Capital Markets	Buy
Jan-30-23	Initiated	BMO Capital Markets	Outperform
Nov-18-22	Initiated	H.C. Wainwright	Buy
Nov-15-22	Upgrade	Goldman	Neutral → Buy
Aug-12-22	Downgrade	SVB Leerink	Outperform → Mkt Perform
Jun-22-22	Initiated	Jefferies	Buy
Jan-04-22	Initiated	SVB Leerink	Outperform
Jan-05-21	Initiated	BofA Securities	Buy
Jan-05-21	Initiated	Evercore ISI	Outperform
Jan-05-21	Initiated	Goldman	Neutral

View All

4 D Molecular Therapeutics Inc Stock (FDMT) Latest News

Mar 19, 2026

4D Molecular Therapeutics (FDMT) Q4 Profit Challenges Longstanding Loss Narrative - simplywall.st

Mar 19, 2026

4D Molecular Therapeutics (FDMT): RBC Capital Raises Price Targe - GuruFocus

Mar 19, 2026

RBC Raises Price Target on 4D Molecular Therapeutics to $35 From $32, Keeps Outperform, Speculative Risk - marketscreener.com

Mar 19, 2026

4D Molecular Therapeutics (FDMT) Reports 2025 Financial Results, Advances 4D-150 Wet AMD Phase 3 Trials, and Extends Cash Runway Into 2028 - Minichart

Mar 19, 2026

Mar 18, 2026

4D Molecular Therapeutics, Inc. 2025 Annual Report: Innovative AAV Gene Therapy Pipeline for Retinal and Pulmonary Diseases - Minichart

Mar 18, 2026